Targeting Histone Deacetylases: A Novel Approach in Parkinson's Disease

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Sharma, Sorabh ^a   Taliyan, Rajeev ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 ORTHOHYDROXYDOPAMINE; ALPHA SYNUCLEIN; ALPHA TUBULIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HEAT SHOCK PROTEIN 90; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KU ANTIGEN; LIPOPOLYSACCHARIDE; NEUROTOXIN; NONHISTONE PROTEIN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CELL CYCLE PROGRESSION; DEACETYLATION; ENZYME INHIBITION; ENZYME ISOLATION; ENZYME PURIFICATION; HISTONE ACETYLATION; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; OLFACTORY DISCRIMINATION; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; RESPIRATORY CHAIN; SYNAPTIC TRANSMISSION; TISSUE SPECIFICITY; TRANSCRIPTION INITIATION;

EID: 84930971150     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/303294     Document Type: Article

References (91)

1. S. Fahn and J. Jankovic, Principles and Practice of Movement Disorders, Churchill Livingstone, Elsevier, Philadelphia, Pa, USA, 2007.
2. S. Sharma, K. Kumar, R. Deshmukh, and P. L. Sharma, "Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders, " European Journal of Pharmacology, vol. 714, no. 1-3, pp. 486-497, 2013.
3. S. Sharma and R. Deshmukh, "Vinpocetine attenuates MPTPinduced motor deficit and biochemical abnormalities inWistar rats, " Neuroscience C, vol. 286, pp. 393-403, 2014.
4. T. T. Warner and A. H. V. Schapira, "Genetic and environmental factors in the cause of Parkinson's disease, " Annals of Neurology, vol. 53, no. 3, pp. S16-S25, 2003.
5. Z. Konsoula and F. A. Barile, "Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders, " Journal of Pharmacological and Toxicological Methods, vol. 66, no. 3, pp. 215-220, 2012.
6. G. Sadri-Vakili and J.-H. J. Cha, "Histone deacetylase inhibitors: a novel therapeutic approach to huntington's disease (complex mechanism of neuronal death), " Current Alzheimer Research, vol. 3, no. 4, pp. 403-408, 2006.
7. I. F. Harrison and D. T. Dexter, "Epigenetic targeting of histone deacetylase: Terapeutic potential in Parkinson's disease?" Pharmacology &Therapeutics, vol. 140, no. 1, pp. 34-52, 2013.
8. A. Giralt, M. Puigdellvol, O. Carretón et al., "Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity, " Human Molecular Genetics, vol. 21, no. 6, pp. 1203-1216, 2012.
9. H. Jia, R. J. Kast, J. S. Steffan, and E. A. Thomas, "Selective histone deacetylase (HDAC) inhibition imparts beneficial effectsin Huntington's disease mice: implications for the ubiquitinproteasomal and autophagy systems, " HumanMolecular Genetics, vol. 21, no. 24, pp. 5280-5293, 2012.
10. K. Xu, X.-L. Dai, H.-C. Huang, and Z.-F. Jiang, "Targeting HDACs: a promising therapy for Alzheimer's disease, " Oxidative Medicine and Cellular Longevity, vol. 2011, Article ID 143269, 5 pages, 2011.
11. S. Sharma, R. Taliyan, and S. Ramagiri, "Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice, " Journal of Molecular Neuroscience, 2014.
12. S. Sharma and R. Taliyan, "Synergistic effects of GSK-3 and HDAC inhibitors in intracerebroventricular streptozotocininduced cognitive deficits in rats, " Naunyn-Schmiedeberg's Archives of Pharmacology, 2014.
13. J. P. Lopez-Atalaya, S. Ito, L. M. Valor, E. Benito, and A. Barco, "Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition, " Nucleic Acids Research, vol. 41, no. 17, pp. 8072-8084, 2013.
14. G. P. Delcuve, D. H. Khan, and J. R. Davie, "Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors, " Clinical Epigenetics, vol. 4, no. 1, article 5, 2012.
15. E. Verdin, F. Dequiedt, and H. G. Kasler, "Class II histone deacetylases: versatile regulators, " Trends in Genetics, vol. 19, no. 5, pp. 286-293, 2003.
16. X. J. Yang and E. Seto, "The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men, " Nature Reviews Molecular Cell Biology, vol. 9, no. 3, pp. 206-218, 2008.
17. M. Dokmanovic and P. A. Marks, "Prospects: histone deacetylase inhibitors, " Journal of Cellular Biochemistry, vol. 96, no. 2, pp. 293-304, 2005.
18. W. Zhao, J.-P. Kruse, Y. Tang, S. Y. Jung, J. Qin, and W. Gu, "Negative regulation of the deacetylase SIRT1 byDBC1, " Nature, vol. 451, no. 7178, pp. 587-590, 2008.
19. M. A. Glozak, N. Sengupta, X. Zhang, and E. Seto, "Acetylation and deacetylation of non-histone proteins, " Gene, vol. 363, no. 1-2, pp. 15-23, 2005.
20. S. Spange, T. Wagner, T. Heinzel, and O. H. Krämer, "Acetylation of non-histone proteins modulates cellular signalling at multiple levels, " International Journal of Biochemistry and Cell Biology, vol. 41, no. 1, pp. 185-198, 2009.
21. R. S. Broide, J. M. Redwine, N. Aftahi, W. Young, F. E. Bloom, and C. J. Winrow, "Distribution of histone deacetylases 1-11 in the rat brain, " Journal of Molecular Neuroscience, vol. 31, no. 1, pp. 47-58, 2007.
22. A. K. B. Lucio-Eterovic, M. A. A. Cortez, E. T. Valera et al., "Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas, " BMC Cancer, vol. 8, article 243, 2008.
23. S. Baltan, A. Bachleda, R. S. Morrison, and S. P. Murphy, "Expression of histone deacetylases in cellular compartments of the mouse brain and the effects of ischemia, " Translational Stroke Research, vol. 2, no. 3, pp. 411-423, 2011.
24. C. Janssen, S. Schmalbach, S. Boeselt, A. Sarlette, R. Dengler, and S. Petri, "Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis, " Journal of Neuropathology and Experimental Neurology, vol. 69, no. 6, pp. 573-581, 2010.
25. E. Hu, Z. Chen, T. Fredrickson et al., "Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor, " Journal of Biological Chemistry, vol. 275, no. 20, pp. 15254-15264, 2000.
26. C. M. Grozinger, C. A. Hassig, and S. L. Schreiber, "Three proteins define a class of human histone deacetylases related to yeast Hda1p, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 9, pp. 4868-4873, 1999.
27. T. A. Bolger and T.-P. Yao, "Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death, " Journal of Neuroscience, vol. 25, no. 41, pp. 9544-9553, 2005.
28. N. M. Tsankova, O. Berton, W. Renthal, A. Kumar, R. L. Neve, and E. J. Nestler, "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action, " Nature Neuroscience, vol. 9, no. 4, pp. 519-525, 2006.
29. C. L. Benn, R. Butler, L. Mariner et al., "Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease, " PLoS ONE, vol. 4, no. 6, Article ID e5747, 2009.
30. W. Zhou, K. Bercury, J. Cummiskey, N. Luong, J. Lebin, and C. R. Freed, "Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease, " Journal of Biological Chemistry, vol. 286, no. 17, pp. 14941-14951, 2011.
31. B. Lang, T. M. Alrahbeni, D. S. Clair, D. H. Blackwood, C. D. McCaig, and S. Shen, "HDAC9 is implicated in schizophrenia and expressed specifically in post-mitotic neurons but not in adult neural stem cells, " American Journal of Stem Cells, vol. 1, no. 1, pp. 31-41, 2011.
32. C. M. Southwood, M. Peppi, S. Dryden, M. A. Tainsky, and A. Gow, "Microtubule deacetylases, SirT2 and HDAC6, in the nervous system, " Neurochemical Research, vol. 32, no. 2, pp. 187-195, 2007.
33. H. Y. Kao, C. H. Lee, A. Komarov, C. C. Han, and R. M. Evans, "Isolation and characterization ofmammalianHDAC10, a novel histone deacetylase, " The Journal of Biological Chemistry, vol. 277, no. 1, pp. 187-193, 2002.
34. L. Gao, M. A. Cueto, F. Asselbergs, and P. Atadja, "Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family, " Journal of Biological Chemistry, vol. 277, no. 28, pp. 25748-25755, 2002.
35. C. Rouaux, N. Jokic, C. Mbebi, S. Boutillier, J. P. Loeffler, and A. L. Boutillier, "Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration, " The EMBO Journal, vol. 22, no. 24, pp. 6537-6549, 2003.
36. G. Sadri-Vakili, B. Bouzou, C. L. Benn et al., "Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models, " Human Molecular Genetics, vol. 16, no. 11, pp. 1293-1306, 2007.
37. E. Kontopoulos, J. D. Parvin, and M. B. Feany, "-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity, " Human Molecular Genetics, vol. 15, no. 20, pp. 3012-3023, 2006.
38. V. Allfrey, "Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 51, pp. 786-794, 1964.
39. M. G. Riggs, R. G. Whittaker, J. R. Neumann, and V. M. Ingram, "n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells, " Nature, vol. 268, no. 5619, pp. 462-464, 1977.
40. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, "Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A, " The Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174-17179, 1990.
41. J. Taunton, C. A. Hassig, and S. L. Schreiber, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p, " Science, vol. 272, no. 5260, pp. 408-411, 1996.
42. W.-M. Yang, C. Inouye, Y. Zeng, D. Bearss, and E. Seto, "Transcriptional repression by YY1 is mediated by interaction with amammalian homolog of the yeast global regulatorRPD3, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 12845-12850, 1996.
43. S. Emiliani, W. Fischle, C. Van Lint, Y. Al-Abed, and E. Verdin, "Characterization of a human RPD3 ortholog, HDAC3, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 6, pp. 2795-2800, 1998.
44. R. A. Frye, "Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (Sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity, " Biochemical and Biophysical Research Communications, vol. 260, no. 1, pp. 273-279, 1999.
45. H.-Y. Kao, M. Downes, P. Ordentlich, and R. M. Evans, "Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression, " Genes and Development, vol. 14, no. 1, pp. 55-66, 2000.
46. J. J. Buggy, M. L. Sideris, P. Mak, D. D. Lorimer, B. McIntosh, and J. M. Clark, "Cloning andcharacterizationofanovelhuman histone deacetylase, HDAC8, " Biochemical Journal, vol. 350, no. 1, pp. 199-205, 2000.
47. I. Van Den Wyngaert, W. De Vries, A. Kremer et al., "Cloning and characterization of human histone deacetylase 8, " FEBS Letters, vol. 478, no. 1-2, pp. 77-83, 2000.
48. X. Zhou, P. A. Marks, R. A. Rifkind, and V. M. Richon, "Cloning and characterization of a histone deacetylase, HDAC9, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10572-10577, 2001.
49. A. R. Guardiola and T. P. Yao, "Molecular cloning and characterization of a novel histone deacetylase HDAC10, " The Journal of Biological Chemistry, vol. 277, no. 5, pp. 3350-3356, 2002.
50. J. J. Tong, J. Liu, N. R. Bertos, and X.-J. Yang, "Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain, "Nucleic Acids Research, vol. 30, no. 5, pp. 1114-1123, 2002.
51. D. D. Fischer, R. Cai, U. Bhatia et al., "Isolation and characterization of a novel class II histone deacetylase, HDAC10, " The Journal of Biological Chemistry, vol. 277, no. 8, pp. 6656-6666, 2002.
52. P. A. Marks and R. Breslow, "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug, " Nature Biotechnology, vol. 25, no. 1, pp. 84-90, 2007.
53. J. M. Wagner, B. Hackanson, M. Lübbert, andM. Jung, "Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy, " Clinical Epigenetics, vol. 1, no. 3-4, pp. 117-136, 2010.
54. G. Gardian, L. Yang, C. Cleren, N. Y. Calingasan, P. Klivenyi, and M. F. Beal, "Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity, " NeuroMolecular Medicine, vol. 5, no. 3, pp. 235-241, 2004.
55. G. Gardian, S. E. Browne, D. K. Choi et al., "Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease, " The Journal of Biological Chemistry, vol. 280, no. 1, pp. 556-563, 2005.
56. M. Zhu, W.-W. Li, andC.-Z. Lu, "Histone decacetylase inhibitors preventmitochondrial fragmentation and elicit early neuroprotection against MPP+, " CNS Neuroscience & Therapeutics, vol. 20, no. 4, pp. 308-316, 2014.
57. R. St. Laurent, L. M. O'Brien, and S. T. Ahmad, "Sodium butyrate improves locomotor impairment and earlymortality in a rotenone-induced Drosophila model of Parkinson's disease, " Neuroscience, vol. 246, pp. 382-390, 2013.
58. J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, "Chronic parkinsonism in humans due to a product of meperidineanalog synthesis, " Science, vol. 219, no. 4587, pp. 979-980, 1983.
59. A. A. Castro, K. Ghisoni, A. Latini, J. Quevedo, C. I. Tasca, and R. D. S. Prediger, "Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) rat model of Parkinson's disease, " Behavioural Brain Research, vol. 229, no. 1, pp. 208-215, 2012.
60. G. Faraco, T. Pancani, L. Formentini et al., "Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain, " Molecular Pharmacology, vol. 70, no. 6, pp. 1876-1884, 2006.
61. E. C. Hirsch and S. Hunot, "Neuroinflammation in Parkinson's disease: a target for neuroprotection" The Lancet Neurology, vol. 8, no. 4, pp. 382-397, 2009.
62. S. A. Zaitone, D. M. Abo-Elmatty, and S. M. Elshazly, "Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats, " Indian Journal of Pharmacology, vol. 44, no. 6, pp. 774-779, 2012.
63. H. L. Martin and P. Teismann, "Glutathione-a review on its role and significance in Parkinson's disease, "TheFASEB Journal, vol. 23, no. 10, pp. 3263-3272, 2009.
64. A. Roy, A. Ghosh, A. Jana et al., "Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mousemodels of Parkinson's disease, " PLoS ONE, vol. 7, no. 6, Article ID e38113, 2012.
65. A. Mehta, M. Prabhakar, P. Kumar, R. Deshmukh, and P. L. Sharma, "Excitotoxicity: bridge to various triggers in neurodegenerative disorders, " European Journal of Pharmacology, vol. 698, no. 1-3, pp. 6-18, 2013.
66. J.-Y. Wu, F.-N. Niu, R. Huang, and Y. Xu, "Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A, " NeuroReport, vol. 19, no. 12, pp. 1209-1212, 2008.
67. P.-S. Chen, G.-S. Peng, G. Li et al., "Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes, " Molecular Psychiatry, vol. 11, no. 12, pp. 1116-1125, 2006.
68. N. B. Chauhan, G. J. Siegel, and J. M. Lee, "Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain, " Journal of Chemical Neuroanatomy, vol. 21, no. 4, pp. 277-288, 2001.
69. D. W. Howells, M. J. Porritt, J. Y. F. Wong et al., "Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra, " Experimental Neurology, vol. 166, no. 1, pp. 127-135, 2000.
70. X. Wu, P. S. Chen, S. Dallas et al., "Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons, " International Journal of Neuropsychopharmacology, vol. 11, no. 8, pp. 1123-1134, 2008.
71. S. Yasuda, M. H. Liang, Z. Marinova, A. Yahyavi, and D. M. Chuang, "Themood stabilizers lithiumand valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons, "Molecular Psychiatry, vol. 14, no. 1, pp. 51-59, 2009.
72. S. K. Kidd and J. S. Schneider, "Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition, " Brain Research, vol. 1354, pp. 172-178, 2010.
73. S. K. Kidd and J. S. Schneider, "Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridinemouse model of Parkinson's disease, " Neuroscience, vol. 194, pp. 189-194, 2011.
74. S. H. Chen, H. M. Wu, B. Ossola et al., "Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage, " British Journal of Pharmacology, vol. 165, no. 2, pp. 494-505, 2012.
75. A. Samii, J. G. Nutt, and B. R. Ransom, "Parkinson's disease, " The Lancet, vol. 363, no. 9423, pp. 1783-1793, 2004.
76. T. H. Johnston, P. Huot, S. Damude et al., "RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study, " Parkinsonism and Related Disorders, vol. 19, no. 2, pp. 260-264, 2013.
77. B. Monti, E. Polazzi, L. Batti, C. Crochemore, M. Virgili, and A. Contestabile, "Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death, " Journal of Neurochemistry, vol. 103, no. 2, pp. 518-530, 2007.
78. B. Monti, D. Mercatelli, and A. Contestabile, "Valproic acid neuroprotection in 6-OHDA lesioned rat, a model for Parkinson's Disease, " HOAJ Biology, vol. 1, no. 1, pp. 1-4, 2012.
79. P. Rane, J. Shields, M. Heffernan, Y. Guo, S. Akbarian, and J. A. King, "The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD, " Neuropharmacology, vol. 62, no. 7, pp. 2409-2412, 2012.
80. R. Betarbet, R. M. Canet-Aviles, T. B. Sherer et al., "Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system, " Neurobiology of Disease, vol. 22, no. 2, pp. 404-420, 2006.
81. B. Monti, V. Gatta, F. Piretti, S. S. Raffaelli, M. Virgili, and A. Contestabile, "Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of-synuclein, " Neurotoxicity Research, vol. 17, no. 2, pp. 130-141, 2010.
82. X. Wang, Z.-H. Qin, Y. Leng et al., "Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells, " Journal of Neurochemistry, vol. 83, no. 5, pp. 1094-1102, 2002.
83. T. Pan, X. Li, W. Xie, J. Jankovic, and W. Le, "Valproic acidmediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells, " FEBS Letters, vol. 579, no. 30, pp. 6716-6720, 2005.
84. M. Inden, Y. Kitamura, H. Takeuchi et al., "Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone, " Journal of Neurochemistry, vol. 101, no. 6, pp. 1491-1504, 2007.
85. B. H. Meurers, C. Zhu, P. O. Fernagut et al., "Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo, " Neurobiology of Disease, vol. 33, no. 2, pp. 182-192, 2009.
86. G. S. Peng, G. Li, N. S. Tzeng et al., "Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia, " Molecular Brain Research, vol. 134, no. 1, pp. 162-169, 2005.
87. P. S. Chen, C.-C. Wang, C. D. Bortner et al., "Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity, " Neuroscience, vol. 149, no. 1, pp. 203-212, 2007.
88. H.-S. Suh, S. Choi, P. Khattar, N. Choi, and S. C. Lee, "Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes, " Journal of Neuroimmune Pharmacology, vol. 5, no. 4, pp. 521-532, 2010.
89. T. F. Outeiro, E. Kontopoulos, S. M. Altmann et al., "Sirtuin 2 inhibitors rescue-synuclein-mediated toxicity in models of Parkinson's disease, " Science, vol. 317, no. 5837, pp. 516-519, 2007.
90. J. Nutt, A. Williams, C. Plotkin, N. Eng, M. Ziegler, and D. B. Calne, "Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations, " Canadian Journal of Neurological Sciences, vol. 6, no. 3, pp. 337-343, 1979.
91. P. A. Price, J. D. Parkes, and C. D. Marsden, "Sodium valproate in the treatment of levodopa-induced dyskinesia, " Journal of Neurology Neurosurgery and Psychiatry, vol. 41, no. 8, pp. 702-706, 1978.